BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 28506909)

  • 1. The selective effect of glycyrrhizin and glycyrrhetinic acid on topoisomerase IIα and apoptosis in combination with etoposide on triple negative breast cancer MDA-MB-231 cells.
    Cai Y; Zhao B; Liang Q; Zhang Y; Cai J; Li G
    Eur J Pharmacol; 2017 Aug; 809():87-97. PubMed ID: 28506909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta.
    Zhou Z; Zwelling LA; Ganapathi R; Kleinerman ES
    Br J Cancer; 2001 Sep; 85(5):747-51. PubMed ID: 11531262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain.
    Qin Y; Meng L; Hu C; Duan W; Zuo Z; Lin L; Zhang X; Ding J
    Mol Cancer Ther; 2007 Sep; 6(9):2429-40. PubMed ID: 17876042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Licorice compounds glycyrrhizin and 18beta-glycyrrhetinic acid are potent modulators of bile acid-induced cytotoxicity in rat hepatocytes.
    Gumpricht E; Dahl R; Devereaux MW; Sokol RJ
    J Biol Chem; 2005 Mar; 280(11):10556-63. PubMed ID: 15642733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells.
    Zhou Z; Zwelling LA; Kawakami Y; An T; Kobayashi K; Herzog C; Kleinerman ES
    Cancer Res; 1999 Sep; 59(18):4618-24. PubMed ID: 10493516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells.
    Torki S; Soltani A; Shirzad H; Esmaeil N; Ghatrehsamani M
    Biomed Pharmacother; 2017 Aug; 92():39-45. PubMed ID: 28528184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of 13H-benzo[f]chromeno[4,3-b][1,7]naphthyridines and their salts as potent cytotoxic agents and topoisomerase I/IIα inhibitors.
    Arepalli SK; Lee C; Sim S; Lee K; Jo H; Jun KY; Kwon Y; Kang JS; Jung JK; Lee H
    Bioorg Med Chem; 2018 Oct; 26(18):5181-5193. PubMed ID: 30253887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with gefitinib or lapatinib induces drug resistance through downregulation of topoisomerase IIα expression.
    Bhosle J; Kiakos K; Porter AC; Wu J; Makris A; Hartley JA; Hochhauser D
    Mol Cancer Ther; 2013 Dec; 12(12):2897-908. PubMed ID: 24092808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (-)-Xanthatin induces the prolonged expression of c-Fos through an N-acetyl-L-cysteine (NAC)-sensitive mechanism in human breast cancer MDA-MB-231 cells.
    Takeda S; Nishimura H; Koyachi K; Matsumoto K; Yoshida K; Okamoto Y; Amamoto T; Shindo M; Aramaki H
    J Toxicol Sci; 2013; 38(4):547-57. PubMed ID: 23824011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycyrrhetinic acid induces cytoprotective autophagy via the inositol-requiring enzyme 1α-c-Jun N-terminal kinase cascade in non-small cell lung cancer cells.
    Tang ZH; Zhang LL; Li T; Lu JH; Ma DL; Leung CH; Chen XP; Jiang HL; Wang YT; Lu JJ
    Oncotarget; 2015 Dec; 6(41):43911-26. PubMed ID: 26549806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
    Chen S; Gomez SP; McCarley D; Mainwaring MG
    Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective effects of glycyrrhizic acid and 18beta-glycyrrhetinic acid in PC12 cells via modulation of the PI3K/Akt pathway.
    Kao TC; Shyu MH; Yen GC
    J Agric Food Chem; 2009 Jan; 57(2):754-61. PubMed ID: 19105645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
    Badinloo M; Esmaeili-Mahani S
    Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18α-Glycyrrhetinic acid lethality for neuroblastoma cells via de-regulating the Beclin-1/Bcl-2 complex and inducing apoptosis.
    Rahman MA; Bishayee K; Habib K; Sadra A; Huh SO
    Biochem Pharmacol; 2016 Oct; 117():97-112. PubMed ID: 27520483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells.
    Kumar A; Ehrenshaft M; Tokar EJ; Mason RP; Sinha BK
    Biochim Biophys Acta; 2016 Jul; 1860(7):1519-27. PubMed ID: 27095671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
    Harris LN; Yang L; Tang C; Yang D; Lupu R
    Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CS1 is a novel topoisomerase IIα inhibitor with favorable drug resistance profiles.
    Shen Y; Chen W; Zhao B; Hao H; Li Z; Lu C; Shen Y
    Biochem Biophys Res Commun; 2014 Oct; 453(3):302-8. PubMed ID: 25242524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
    Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
    Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors.
    Oloumi A; MacPhail SH; Johnston PJ; Banáth JP; Olive PL
    Cancer Res; 2000 Oct; 60(20):5747-53. PubMed ID: 11059769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.